A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

Advanced Solid Tumor Clinical Trial

Official title:

A Multicenter, Open-label, Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of SOT201 in Patients With Advanced/Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06163391
• Other study ID #: SC201
• Secondary ID: VICTORIA-012023-
• Status: Recruiting
• Phase: Phase 1
• Start date: May 9, 2024
• Est. completion date: October 2026

Study information

• Verified date: May 2024
• Source: Sotio Biotech Inc.
• Contact: Richard Kapsa
• Phone: (+420) 2241 74448
• Email: kapsa[@]sotio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors

During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined

Description:

Duration of the study for a participant will include:

Screening period: Up to 21 days before day 1 of cycle 1 (can be prolonged up to 42 days, if required due to fresh biopsy) Treatment Period: enrolled and exposed participants will receive continuous treatment until progressive disease (PD), or an occurrence of an unacceptable AE, a withdrawal of consent, or until other permanent discontinuation criteria described in the protocol are met.

End of treatment will occur within 7 (+7) days after the SOT201 discontinuation, and Follow-up period.

Every 30 (±2) days until 90 (+7) days after the final dose of SOT201, until disease progression, the start of new anticancer therapy, death, or withdrawal of participant's consent, whichever comes first.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 2026
• Est. primary completion date: October 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Criteria: Inclusion criteria:

Type of patients

• Patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have disease progression after treatment with available therapies for their disease that are known to confer clinical benefit

• Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology; lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

• Accessible tumor tissue available for fresh biopsy or being considered for tumor biopsy according to the treating institution's guidelines and willing to undergo a new biopsy if not clinically contraindicated Note: Newly obtained tumor tissue (to be taken at baseline) is preferred to an archival sample. All tumor biopsies will be collected from the same target lesion, if possible. Archived, fixed tumor tissue may only be collected (taken ideally after completion of the most recent systemic tumor therapy and within 6 months prior to the first dose of trial treatment) if fresh biopsy at screening cannot be retrieved from patients due to safety concerns.

• Performance status: Eastern Cooperative Oncology Group (ECOG) performance score 0-1

• Must have recovered from all adverse events (AEs) due to previous therapies to grade =1 toxicity (excluding alopecia) or have stable grade 2 neuropathy as per investigators judgement Note: grade >1 immune- related AEs to any prior treatments may be accepted if considered clinically nonsignificant and/or clinically stable on supportive therapy.

• Organ function: Have adequate organ function during screening and prior to first SOT201 dose.

Exclusion criteria:

Prior/concomitant therapy

• Known clinically relevant intolerability or severe hypersensitivity to prior anti PD-1 or anti-PD-L1 agent therapy, pembrolizumab and/or any of its excipients, or an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, CD134 [OX40], CD137) that caused permanent discontinuation of the agent, or that were grade 4 in severity or have not resolved to grade =1.

• Prior exposure to drugs that are agonists or antagonists of IL-2, IL-4, IL-7, IL-8, IL-9, IL-12, IL-15, IL-18, IL-21 or IL-27 prior to ICF signature.

• Prior systemic anti-cancer therapies, including investigational agents, prior to day 1 cycle 1 signature if not otherwise indicated:

• Less than 3 weeks for all systemic chemotherapy

• Less than 3 weeks or 5 half-lives (whichever shorter) for any biologic agents

• Less than 4 weeks for ICIs (targeting CTLA-4, or PD-L1, including e.g., ipilimumab, atezolizumab, avelumab, durvalumab, cemiplimab) prior to cycle 1 day 1

• Less than 4 weeks from major surgeries and not recovered adequately from the procedure and/or any complications from the surgery before starting SOT201

• Has received radiation therapy =14 days before day 1 of cycle 1 or has not recovered to grade =1 from treatment-related side effects. A 1-week radiation-free period is permitted for palliative radiation (=2 weeks of radiotherapy) to non-central nervous system disease.

• Use of prohibited medication prior or during the course of the trial as specified in the protocol

• Predicted life expectancy =3 months

• Clinically significant cardiac abnormalities

• Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years (patients who have had a transplant more than 5 years ago are eligible as long as there are no symptoms of graft versus host disease)

• Diagnosis of other forms of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of SOT201

• Has a known additional malignancy that is progressing or has required active treatment within the past 5 years. Patients with basal cell carcinoma of the skin or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

• Has known active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during trial screening), clinically stable and without requirement of steroid treatment for at least 14 days before the first dose of SOT201.

• Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

• Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

• Has an active infection requiring systemic therapy, except in cases for treatment of HIV and/or Hepatitis B

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator

NOTE: Other Inclusion/Exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Metastatic Solid Tumor
• Neoplasms

Intervention

Drug:
• SOT201
intravenous infusion

Locations

Country	Name	City	State
Belgium	Institut Jules Bordet	Anderlecht	Brussels
Belgium	Universitair Ziekenhuis Antwerpen (UZA)	Edegem	Antwerp
Czechia	Masarykuv Onkologický Ústav	Brno
Czechia	Fakultni Nemocnice Olomouc (FNOL) - Onkologicka Klinika	Olomouc
France	Institut Gustave Roussy	Paris
Spain	Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)	Barcelona
United States	MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
SOTIO Biotech AG

Countries where clinical trial is conducted

United States,  Belgium,  Czechia,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentages of participants with treatment-emergent adverse events (TEAEs)	A TEAE is defined as an AE that started or worsened at or after the start of trial treatment Presence of TEAEs, SAEs, and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	from patient signing the ICF up to 90 (+7) days after the last dose of SOT201, assessed approximately up to 3 years
Primary	Number of participants with dose-limiting toxicities (DLTs)	DLTs will be defined using NCI CTCAE version 5.0	21 days of Cycle 1 plus 7 days of cycle 2 per cycle
Secondary	Characterization of area under the curve (AUClast, AUCinf, AUCtau) of SOT201	Area under the concentration versus time curve calculated using the trapezoidal method during a dosing interval (tau)	From Day 1 Cycle 1 to Cycle 3, from cycle 4 every other cycle (4, 6, 8), and from cycle 8 at quarterly frequency (11, 14, 17.) until cycle 20
Secondary	Characterization of maximum concentration (Cmax) of SOT201	Maximum plasma concentration observed	Time Frame: From Day 1 of Cycle 1 to Cycle 3, from cycle 4 every other cycle (4, 6, 8), and from cycle 8 at quarterly frequency (11, 14, 17.) until cycle 20]
Secondary	Characterization of time to maximum concentration (Tmax) of SOT201	Time to maximum concentration of SOT201	From Day 1 of Cycle 1 to Cycle 3, from cycle 4 every other cycle (4, 6, 8), and from cycle 8 at quarterly frequency (11, 14, 17..) until cycle 20
Secondary	Characterization of pre-dose concentration (Ctrough) of SOT201	Pre-dose trough SOT201 concentrations	From Day 1 of Cycle 1 to Cycle 3, from cycle 4 every other cycle (4, 6, 8), and from cycle 8 at quarterly frequency (11, 14, 17..) until cycle 20
Secondary	Objective response rate (ORR)	Proportion of patients who have a confirmed complete response (CR) or a partial response (PR), as the best overall response (BOR) determined by the Investigator as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	From Day 1 of Cycle 1 until disease progression or start new anticancer therapy, whichever comes first, assess to up to approximately 3 years
Secondary	Duration of response (iDoR)	DoR is defined as the time from first documented evidence of confirmed CR or PR until progressive disease (PD) determined by Investigator per RECIST 1.1 or death from any cause, whichever occurs first	From Day 1 of Cycle 1 until disease progression or start new anticancer therapy, whichever comes first, assess to up to approximately 3 years
Secondary	Clinical benefit rate (iCBR)	including confirmed CR or PR at any time or stable disease (SD) of at least 6 months determined by Investigator per RECIST 1.1	From Day 1 of Cycle 1 until disease progression or start new anticancer therapy, whichever comes first, assess to up to approximately 3 years
Secondary	Progression-free survival (iPFS)	PFS is defined as the time from the date of first administration of IMP to the date of the first documented disease progression determined by Investigator as per RECIST 1.1 or death from any cause, whichever occurs first	From Day 1 of Cycle 1 until disease progression or start new anticancer therapy, whichever comes first, assess to up to approximately 3 years
Secondary	Incidence of anti-drug antibodies (ADAs) against SOT201	Incidence of patients with anti-drug antibodies	Day 1 until 30 (±2) days after the last dose of SOT201